Ara
Toplam kayıt 3, listelenen: 1-3
Gilteritinib (XOSPATA (R)) in Turkey: Early access program results
(Mattioli 1885, 2023)
Background And Objectives: Gilteritinib (XOSPATA (R), Astellas) is a type I oral FLT3 inhibitor, a tyrosine kinase AXL inhibitor, involved in both c-Kit and FMS-like tyrosine kinase 3 (FLT3) resistance. In the phase 3 ...
Charlson comorbidity index (CCI) in diffuse large B-cell lymphoma: A new approach in a multicenter study
(Springer, 2023)
Purpose: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of adult lymphomas. The incidence of DLBCL increases with age and has a fairly rapid fatal course without treatment. Patients often have difficulty ...
Plerixafor in autologous stem cell transplantation: Does it affect engraftment kinetics?
(Elsevier Ltd, 2023)
Plerixafor increases stem cell mobilization by reversibly binding to the chemokine receptor CXCR4. In our study, we examined the results of mobilization with plerixafor and granulocyte colony-stimulating factor (G-CSF) and ...